DNA Data Marketplace: An Analysis of the Ethical Concerns Regarding the Participation of the Individuals

Abstract

Personal genomic data and the related health data are valuable resources for both public-funded research, and for-profit entities in development of new drugs, therapies, and diagnostic tests. In order to access to large datasets, pharmaceutical and biotech companies have developed partnerships with public and private entities such as direct-to-consumer genetic testing companies to buy genomic and health related databases collected from research participants and customers. Although individuals mainly support data sharing for research purposes, the for-profit nature of such data sharing raises some questions regarding the rights of the data subjects and fairness in sharing benefits. In response, a new generation of sequencing and data sharing startups such as Nebula Genomics, LunaDNA, and EncrypGen are emerging which aim for leaving the data control in the hands of each individual customer. In particular, such so-called “DNA data marketplaces” allow individuals to receive various types of monetary incentives to sequence their genome and share it with interested commercial parties. This paper aims to provide an exploratory and critical review of the ethical challenges related to establishing such marketplaces for genomic and health data sharing. In the view of the growing number of startups developing such marketplaces, a thorough analysis of the relevant ethical concerns is timely and needed.

<p>Informed Consent Form Challenges for Genetic Research in Jordan</p>

“…Different ethical challenges in genetic studies were addressed in previous studies. 20,21 The newly emerging genetic information could affect patients' clinical management and health services. 20 Furthermore, genetic privacy has emerged as a challenging concern that need to be addressed carefully due to its familial sensitivity.…”

The Data Governance Act and the EU's move towards facilitating data sharing

“…Notably, other emerging proposals such as the Data Union (https://thedataunion.eu) or the Data Dividend (Kelly, 2020) projects can, in principle, also facilitate data sharing by individuals for privately funded research. Indeed, this could enable health and DNA data markets for biomedical research sponsored by the private sector, where individuals share their data in exchange for financial incentives (Ahmed & Shabani, 2019). However, monetary incentives in health research have raised ethical and legal concerns, such as imposing undue influence on individuals and questioning the validity of their consent.…”

Impute.me: An Open-Source, Non-profit Tool for Using Data From Direct-to-Consumer Genetic Testing to Calculate and Interpret Polygenic Risk Scores

“…Given that for most complex disorders there is currently a lack of data regarding the harms or benefits of accessing PRS information, the fundamental principle in favor of making PRSs available to the public is that of autonomy—in the context of genetic testing, this refers to “the right of persons to make an informed, independent judgment about whether they wish to be tested and then whether they wish to know the details of the outcome of the testing” ( Andrews et al, 1994 ). Accordingly, currently, DTC users can access health information through portals of DTC providers and through third-party applications ( Kalokairinou et al, 2018 ; Tiller and Lacaze, 2018 ; Ahmed and Shabani, 2019 ). The problem is that many popular websites do not communicate high-quality genetic knowledge, in part possibly owing to the lack of engagement by the research communities ( Badalato et al, 2017 ).…”